난소암 · FRα

155개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved155 programs
ADCCurated CoreFDAstaleRochevedotin, rituximab, cycloph…Phase 3

Polatuzumab Vedotin (Polatuzumab Vedotin)

Large B-Cell Lymphoma · FRα

#FR#ADC#Phase3#FDA-approved#BioJungboMoa-pick+5
Trials 91Status Recruiting
ADCCurated CoreFDAAbbVieDM4 (maytansinoid, tubulin …Approved

mirvetuximab soravtansine (Elahere, IMGN853, mirvetuximab-soravtansine-gynx)

FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer · FRα (folate receptor alpha)

#FRfolatereceptoralpha#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 32Status Approved
AntibodyLimited DatastaleRochePhase 3

Mabthera (Mabthera)

Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 129Status Active
AntibodyCurated CorestaleBristol Myers SquibbPhase 2

Relatlimab (Relatlimab)

Various Advanced Cancer · FRα

#FR#Antibody#Phase2#BioJungboMoa-pick#Popular+4
Trials 74Status Recruiting
ADCStandard DatabasestaleFavrillederuxtecan for metastatic b…Phase 2

Antibody-Drug Conjugate Therapy (Antibody-Drug Conjugate Therapy)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · FRα

#FR#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 58Status Recruiting
AntibodyCurated CorestalePfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#BioJungboMoa-pick#Popular+4
Trials 54Status Recruiting
CGTLimited DatastaleInternational Brain Research Fo…Phase 2

Quercetin (Quercetin)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 54Status Recruiting
CGTStandard DatabasestaleKiteApproved

axicabtagene ciloleucel (Yescarta, axi-cel)

DLBCL; Diffuse Large B Cell Lymphoma · FRα

#FR#CGT#Approved#Popular#cell-gene-therapy+5
Trials 53Status Recruiting
AntibodyLimited DatastalePfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 51Status Active
AntibodyCurated CorestaleEpizyme, Inc.Phase 3

Mosunetuzumab (Mosunetuzumab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · FRα

#FR#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+4
Trials 49Status Recruiting
CGTLimited DatastaleHistograft Co., Ltd.Preclinical

"Histograft", a bone substitute based on octacalcium phosphate (OCP, "Histograft", a bone substitute based on octacalcium phosphate, "Histograft", a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene)

Non Union Fracture; Non-Union of Ankle Joint Without Infection · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 45Status Active
CGTLimited DatastaleSecuraBioPhase 1

Duvelisib (Duvelisib)

Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 45Status Active
CGTStandard DatabasestaleNovartisPhase 3

tisagenlecleucel (Kymriah, tisa-cel)

DLBCL; Diffuse Large B Cell Lymphoma · FRα

#FR#CGT#Phase3#cell-gene-therapy#CAR-T+5
Trials 45Status Recruiting
CGTStandard DatabasestaleOHSU Knight Cancer InstitutePhase 2

Hyper-CVAD (Hyper-CVAD)

Relapsed/Refractory; B-cell Acute Lymphocytic Leukemia · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 40Status Recruiting
AntibodyCurated CorestaleJanssenPhase 3

Talquetamab (Talquetamab)

Myeloma Multiple; Plasma Cell Leukemia · FRα

#FR#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+4
Trials 40Status Discontinued
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

CD4 CAR T cells (CD4 CAR T cells)

T Cell Lymphoma in Relapse; Refractory T-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 39Status Active
CGTLimited DatastaleSung-Soo ParkPreclinical

IMiD treatment (IMiD treatment)

Multiple Myeloma, Relapsed; Multiple Myeloma (MM) · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 39Status Recruiting
CGTLimited DatastaleCartesian TherapeuticsPhase 1

CAR-T (Chimeric Antigen Receptor T Cells, Chimeric Antigen Receptor T Cells (CAR-T))

B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 38Status Recruiting
CGTStandard DatabasestaleNovartis PharmaceuticalsPhase 2

CTL019 T-cells (CTL019 T-cells)

B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 37Status Active
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 1

CAR-T cells chimeric antigen receptor T cells (CAR-T cells chimeric antigen receptor T cells)

AML; Refractory/Relapse Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 33Status Recruiting

1 / 8 pages

← PreviousNext →